|
1
|
Toja-Camba FJ, Bandín-Vilar E, Hermelo-Vidal G, Feitosa-Medeiros C, Cañizo-Outeiriño A, Castro-Balado A, Varela-Rey I, Zarra-Ferro I, Fernández-Ferreiro A, Mondelo-García C. Towards Precision Medicine in Clinical Practice: Alinity C vs. UHPLC-MS/MS in Plasma Aripiprazole Determination. Pharmaceutics 2024; 16:104. [PMID: 38258114 PMCID: PMC10820753 DOI: 10.3390/pharmaceutics16010104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 01/02/2024] [Accepted: 01/11/2024] [Indexed: 01/24/2024] Open
Abstract
Therapeutic drug monitoring improves the benefit-risk balance of antipsychotic therapy. Ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) is considered the gold-standard method for measuring plasma drug concentrations; however, the Alinity C system has emerged as a promising alternative. This is the first study aimed at comparing UHPLC-MS/MS versus Alinity C in measuring plasma concentrations of aripiprazole and dehydroaripiprazole. A total of 86 plasma samples were analyzed. The active moiety of aripiprazole was measured in 60 samples using both systems and 26 samples were analyzed twice using Alinity C with an intermediate period of 6 months to assess its reproducibility. Spearman's correlation revealed a good association between the two assays (rs = 0.96) and no significance differences were found by McNemar's test when classifying samples between infra-, supra- and therapeutic ranges. Passing-Bablock regression showed a good correlation among methods (rs = 0.93) and a slope of 1.12 indicating a slight tendency of Alinity C to measure higher values than UHPLC-MS/MS. In addition, a good intra-method correlation across the two sequential analyses with Alinity C was obtained (rs = 0.99). Nonetheless, clinical decisions could be different in 15% of the cases depending on the chosen method. No differences were found in active moiety determination by Alinity C depending on the concentration of aripiprazole and dehydroaripiprazole of the samples.
Collapse
Affiliation(s)
- Francisco José Toja-Camba
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain; (F.J.T.-C.); (E.B.-V.); (A.C.-B.); (I.V.-R.); (I.Z.-F.)
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
- Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Enrique Bandín-Vilar
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain; (F.J.T.-C.); (E.B.-V.); (A.C.-B.); (I.V.-R.); (I.Z.-F.)
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
- Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Gonzalo Hermelo-Vidal
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
| | - Carolina Feitosa-Medeiros
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
| | - Antonio Cañizo-Outeiriño
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
| | - Ana Castro-Balado
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain; (F.J.T.-C.); (E.B.-V.); (A.C.-B.); (I.V.-R.); (I.Z.-F.)
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
| | - Iria Varela-Rey
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain; (F.J.T.-C.); (E.B.-V.); (A.C.-B.); (I.V.-R.); (I.Z.-F.)
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
| | - Irene Zarra-Ferro
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain; (F.J.T.-C.); (E.B.-V.); (A.C.-B.); (I.V.-R.); (I.Z.-F.)
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
| | - Anxo Fernández-Ferreiro
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain; (F.J.T.-C.); (E.B.-V.); (A.C.-B.); (I.V.-R.); (I.Z.-F.)
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
| | - Cristina Mondelo-García
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain; (F.J.T.-C.); (E.B.-V.); (A.C.-B.); (I.V.-R.); (I.Z.-F.)
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (G.H.-V.); (C.F.-M.); (A.C.-O.)
| |
Collapse
|
|
2
|
Kumbhar SA, Kokare CR, Shrivastava B, Choudhury H. Specific and Sensitive RP-HPLC Method Development and Validation for the Determination of Aripiprazole: Application in Preformulation Screening of Nanoemulsion. ACTA ACUST UNITED AC 2020. [DOI: 10.2174/2468187309666190823155215] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
It has been hypothesized that delivery of aripiprazole through
nanoemulsion formulation would better deliver the drug into the central nervous system
to treat major depressive conditions in psychological patients. Due course of formulation
development, to determine solubility of the drug in different matrices and nanoemulsion
is an important step.
Materials & Methods:
Therefore, a simple, rapid and selective reversed phase high performance
liquid chromatographic (RP-HPLC) method was developed and validated for
the determination of aripiprazole as per International Conference of Harmonization (ICH)
guidelines. Satisfactory analysis method was employed for the quantitative determination
of aripiprazole during pre-formulation development.
Results and Discussion:
The separation technique was achieved using the mobile phases
of methanol-acetonitrile, 80:20 (v/v) delivered at 1.0 mL.min-1 flow rate through HIQ
SIL C18 250x4.6 mm (5 μm particle size) column and detected at 218 nm wavelength.
The method depicted linear calibration plots within the range of 5 to 50 µg.mL-1 with a
determination coefficient (r2) of 0.9991 calculated by least square regression method.
The validated method was sensitive with LOD of 10.0 ng.mL-1 and 30.0 ng.mL-1 of
LOQ. The intra-day and inter-day precision values were ranged between 0.37-0.89 and
0.63-1.11 respectively, with accuracy ranging from 98.24 to 100.88 and 97.03 to 100.88,
respectively. This developed and validated method was found to be sensitive for the determination
of aripiprazole for the first time from various oils, surfactants, co-surfactants,
and nanoemulsion formulation.
Conclusion:
This RP-HPLC method was successfully implemented for the quantitative
determination of aripiprazole at developmental stages of nanoemulsion formulation.
Collapse
Affiliation(s)
- Santosh A. Kumbhar
- School of Pharmaceutical Sciences, Jaipur National University, Jaipur 302 017, Rajasthan, India
| | - Chandrakant R. Kokare
- Department of Pharmaceutics, STES’s Sinhgad Institute of Pharmacy (Affiliated to Savitribai Phule Pune University), Narhe, Pune 411 041, Maharashtra, India
| | - Birendra Shrivastava
- School of Pharmaceutical Sciences, Jaipur National University, Jaipur 302 017, Rajasthan, India
| | - Hira Choudhury
- Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, 57000 Kuala Lumpur, Malaysia
| |
Collapse
|
|
3
|
Schizophrenia: recent advances in LC-MS/MS methods to determine antipsychotic drugs in biological samples. Bioanalysis 2019; 11:215-231. [PMID: 30663320 DOI: 10.4155/bio-2018-0155] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Schizophrenia is one of the most debilitating and costly illnesses worldwide. First-generation antipsychotics such as chlorpromazine and haloperidol succeeded in controlling the positive symptoms of schizophrenia, but had significant extrapyramidal effects that led to the search for new agents and the release of second-generation (or atypical) antipsychotics. These drugs had a lower risk of adverse motor symptoms. Therapeutic drug monitoring has become a useful tool to optimize schizophrenia treatment and HPLC-MS/MS has been considered the primary technique to monitor antipsychotics. This review comprises three sections: schizophrenia pathophysiology and treatment; recent advances in LC-MS/MS methods designed to measure levels of antipsychotics and their metabolites in plasma samples (selectivity, matrix effect and sensitivity); and the importance of therapeutic drug monitoring.
Collapse
|